Cancer Research Cancer Epigenetics  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sacco, M. G.
Right arrow Articles by Vezzoni, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sacco, M. G.
Right arrow Articles by Vezzoni, P.
[Cancer Research 60, 2660-2665, May 15, 2000]
© 2000 American Association for Cancer Research


Experimental Therapeutics

Liposome-delivered Angiostatin Strongly Inhibits Tumor Growth and Metastatization in a Transgenic Model of Spontaneous Breast Cancer1

Maria Grazia Sacco2, Mario Caniatti, Enrica Mira Catò, Annalisa Frattini, Giulia Chiesa, Roberta Ceruti, Fulvio Adorni, Luigi Zecca, Eugenio Scanziani and Paolo Vezzoni

Department of Human Genome and Multifactorial Diseases, Istituto di Tecnologie Biomediche Avanzate, Consiglio Nazionale delle Ricerche, 20090 Segrate Milan [M. G. S., E. M. C., A. F., F. A., L. Z., P. V.]; Istituto di Anatomia Patologica Veterinaria e Patologia Aviare [M. C., R. C., E. S.]; and Istituto di Scienze Farmacologiche, Facoltà di Farmacia, Università di Milano, 20133 Milan [G. C.], Italy

The possibility to inhibit tumor growth by interfering with the formation of new vessels, which most neoplasias depend on, has recently raised considerable interest. An angiogenic switch, in which proliferating cells acquire the ability to direct new vessel formation, is thought to be an early step in the natural history of solid tumors. Using a transgenic model of breast cancer, which shows many similarities to its human counterpart, including ability to metastasize, we targeted angiostatin production to an early stage of tumor formation. Liposome-delivered angiostatin considerably delayed primary tumor growth and, more importantly, inhibited the appearance of lung metastases. These findings can be relevant to the design of therapeutic intervention in humans.




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
M. E. Daly, A. Makris, M. Reed, and C. E. Lewis
Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment?
J Natl Cancer Inst, November 19, 2003; 95(22): 1660 - 1673.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass
Angiogenesis in Endocrine Tumors
Endocr. Rev., October 1, 2003; 24(5): 600 - 632.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. A. Scappaticci
Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.